Search
Novartis Boosts 2025 Outlook Amid Robust First-Quarter Growth
2025-04-29 /
Read about 0 minute
Author：小编
On Tuesday, the Swiss pharmaceutical giant Novartis unveiled an upbeat full-year earnings forecast, buoyed by the impressive first-quarter performance of drugs such as Leqvio, Kisqali, and Kesimpta. The company now anticipates achieving "low double-digit" growth in operating profit, excluding non-recurring items, by 2025. This marks an upward revision from its previous forecast of "high single-digit to low double-digit" growth. Notably, Novartis reported a robust 22% growth in actual operating profit for 2024.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
